There is a strange gap between saying “I can afford cryopreservation” and actually having it funded.
A person may have a good salary, a valuable apartment, investments and a family that supports the decision. On paper, the money exists.
Then legal death happens on a Sunday morning. The bank account is frozen, the market is closed and the relative who promised to help is overwhelmed, uncertain or suddenly against the idea.
Tomorrow.bio cannot build an emergency operation around money that might arrive.
A working funding method has to do something much more specific. It must provide enough money, through a route Tomorrow.bio has accepted, at the time the procedure needs to begin.
That sounds obvious. Honestly, it is where many sensible arrangements become fragile.
A promise is not funding
We have seen members assume that a partner or relative would make the payment after death. The family may have meant it when they agreed.
But that agreement still leaves the decisive action with someone else, at the worst possible moment.
Grief changes people. Family disagreements appear. Money that felt available yesterday becomes an inheritance question today.
Sometimes nobody calls us at all.
This is why an arrangement should not depend on your family choosing to fund it after you die. They can support the procedure, notify us and help with documents. They should not be the only thing standing between a signed contract and an unfunded case.
A Last Will does not solve the timing problem. Tomorrow.bio’s current funding guide explicitly says that Last Will arrangements are not accepted as an alternative funding method.
The reasons are practical: estate payments can be delayed, disputed or taxed, while cryopreservation costs begin immediately.
You should still complete the relevant documents that record your wishes. They serve a different purpose. They do not replace a working payment route.
This distinction matters because signing the contract feels like the big moment. It is a big moment.
It is just not the last one.
For most members, insurance is the cleanest route
Life insurance exists for exactly this kind of timing problem. You pay premiums while alive, and the policy provides a defined death benefit when the insured person dies.
You do not need to hold the full cryopreservation amount in cash throughout your life.
Tomorrow.bio currently lists member prices of €200,000 for whole-body cryopreservation and €75,000 for brain-only cryopreservation. Its funding-minimum policy states that the version published when the contract is signed is legally binding for that contract.
Check your own agreement and Memberzone rather than relying on a number remembered from an old article.
For members using a local term-life insurer, Tomorrow.bio’s current instruction is to designate Tomorrow Biostasis GmbH as beneficiary. Its European insurance partner can also manage the application and underwriting process for eligible members.
The beneficiary detail is not administrative decoration. It is what allows the payout to move toward the cryopreservation instead of becoming a new family decision.
Term-life insurance is often the cheapest way to secure a large amount, especially when arranged while young and healthy. The weakness is in the name: the policy covers a term.
If it expires at seventy and cannot be renewed on workable terms, the funding disappears with it.
Whole-life insurance avoids a fixed end date as long as the required premiums continue, but it is usually more expensive. Tomorrow.bio’s current European guide offers a specific whole-life route only for residents of Germany.
The better answer depends on age, health, country, budget and how you plan to fund the later decades of life. Term and whole-life insurance explains that trade-off in more detail.
This article cannot tell you which financial product to buy. Tomorrow.bio can confirm whether a proposed route satisfies its operational requirements, while a qualified adviser or insurer can address the personal financial decision.
There is one more detail people underestimate: applying for insurance is not the same as having insurance.
The policy must be issued. The coverage amount and beneficiary must be correct. Premiums must remain paid, and Tomorrow.bio needs the supporting documentation.
Other methods need case-specific acceptance
Insurance is common, but it is not the only possible route.
Tomorrow.bio’s official funding guide also describes trusts, pre-payment, direct payment and case-by-case alternative arrangements. Each solves a different problem, and none should be assumed to work without prior approval.
A UK discretionary trust can combine funding for the procedure with a longer-term financial structure. It is a legal and tax arrangement, not a form you should improvise from an online example.
Professional advice is essential, and Tomorrow.bio still needs to confirm how the cryopreservation payment will become available.
Pre-payment is more restricted than people sometimes assume. The current Tomorrow.bio guide says it is accepted for a patient with a confirmed prognosis of less than twelve months.
Direct payment can also apply when someone is critically ill or has recently died and the case is already urgent.
These are time-sensitive routes, not a general recommendation that every healthy member transfer the full amount years in advance.
Other proposed arrangements are evaluated individually. The common requirement is immediate liquidity before the cryopreservation procedure.
An investment account may look large enough but still fail that test. Assets may need to be sold, trades settled and taxes paid. Accounts can be restricted after death.
A property is even clearer. It may be worth far more than the required amount and still be useless for paying an emergency invoice this week.
“But my family can bridge the gap” brings us back to the original problem.
If the method needs a relative to understand the plan, agree again, find the money and send it quickly, the method is still dependent on that relative.
Family-funded cryopreservation at death explains why good intentions are not enough here. Independent funding protects both the member and the family from having to renegotiate the decision during grief.
Finish the setup, then keep it alive
A few member interviews revealed a very ordinary source of anxiety: people had signed up, liked Tomorrow.bio and still were not sure whether the insurance side was actually complete.
That feeling is useful information. It usually means the arrangement has not yet produced a clear written answer.
The endpoint is not “I bought a policy.” It is “Tomorrow.bio has reviewed the evidence and confirmed that my funding method is accepted.”
Upload the current documents through the Memberzone. Confirm the insured amount, beneficiary and policy status. If the funding structure is unusual, discuss it with Tomorrow.bio before relying on it.
Then review it when life changes.
A move to another country can affect insurance and legal structures. A missed premium can end coverage. A separation can change beneficiaries and emergency contacts.
Even an arrangement that worked perfectly ten years ago deserves another look.
This does not mean turning cryopreservation funding into a second job. It means checking the few facts that decide whether the system still works.
Is the amount sufficient under your contract? Is the method active? Has Tomorrow.bio accepted it? Can the money arrive without waiting for your family to choose?
If all four answers are yes, you have moved from “maybe” to “done” on the financial side.
That is the point of the whole exercise. Not to look wealthy on paper, but to make your decision survive the moment when you can no longer explain or defend it yourself.
TL;DR: Your funding is ready only when the amount is sufficient, Tomorrow.bio has accepted the method and the money can arrive without your family deciding to pay after your death. Confirm the arrangement in writing and review it when your circumstances change.
Further reading